NCT03685045 ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings
| NCT ID | NCT03685045 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kirby Institute |
| Condition | Hepatitis C |
| Study Type | INTERVENTIONAL |
| Enrollment | 6,000 participants |
| Start Date | 2018-05-28 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 6,000 participants in total. It began in 2018-05-28 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall goals of the ETHOS II Project are to enhance hepatitis C virus (HCV) care in drug treatment clinics and needle and syringe programs (NSPs) in New South Wales and Australia, and to develop a translational framework for subsequent establishment of HCV screening and treatment programs in drug treatment clinics and NSPs across NSW and nationally.
Eligibility Criteria
Inclusion Criteria: * Participant has voluntarily signed the informed consent form; * 18 years of age or older; * History of injecting drug use\*; * Recent injecting drug use (previous six months) or currently receiving OST\*. * These criteria will not apply for recruitment from residential rehabilitation centres Exclusion Criteria: * Nil
Contact & Investigator
Jason Grebely
STUDY CHAIR
The University of New South Wales
Frequently Asked Questions
Who can join the NCT03685045 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatitis C. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03685045 currently recruiting?
Yes, NCT03685045 is actively recruiting participants. Contact the research team at dsilk@kirby.unsw.edu.au for enrollment information.
Where is the NCT03685045 trial being conducted?
This trial is being conducted at Canberra, Australia, Blacktown, Australia, Brookvale, Australia, Campbelltown, Australia and 11 additional locations.
Who is sponsoring the NCT03685045 clinical trial?
NCT03685045 is sponsored by Kirby Institute. The principal investigator is Jason Grebely at The University of New South Wales. The trial plans to enroll 6,000 participants.